Venrock

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Suki develops AI-driven voice solutions for healthcare providers. Its primary product, Suki Assistant, uses artificial intelligence and natural language processing to create detailed clinical notes during or after consultations, enabling physicians to complete administrative tasks more efficiently.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company dedicated to the identification, development, and commercialization of products aimed at addressing cardiovascular and pulmonary diseases with significant unmet medical needs. Headquartered in Morrisville, North Carolina, Tenax focuses on levosimendan, a pharmaceutical product designed to reduce morbidity and mortality in cardiac surgery patients at risk for low cardiac output syndrome. The company is also actively conducting a Phase 2 clinical trial to explore the efficacy of levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction. Additionally, Tenax is involved in developing novel formulations of imatinib mesylate, a kinase inhibitor with the potential to serve as a disease-modifying therapy for pulmonary arterial hypertension. Founded in 1967, Tenax Therapeutics underscores its commitment to advancing treatments within these critical therapeutic areas.

CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Tenaya Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for heart disease and heart failure. It operates three product platforms: cellular regeneration, which aims to regenerate heart tissue by reprogramming cardiac fibroblasts into cardiomyocytes via delivery of proprietary transcription factors; gene therapy, which targets cardiac fibroblasts to deliver therapeutic payloads; and precision medicine, which enables personalized approaches to treat heart disease. Founded in 2016 and headquartered in South San Francisco, California, Tenaya seeks to address the underlying cellular pathologies of diseased myocardium with curative therapies that advance from discovery through development.

Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies to treat ocular diseases. Its pipeline includes ADVM-022 for wet age-related macular degeneration, ADVM-043 for alpha-1 antitrypsin deficiency, and preclinical candidates for other indications.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Accompany Health provides comprehensive in-home primary care, including chronic illness management and treatment of new symptoms, and coordinates care across the full patient journey. The company offers at-home and virtual care, with round-the-clock support to address health needs any time, day or night. It focuses on cultivating long-term relationships with patients, ensuring consistent access to care and a stable point of contact year after year. Accompany Health serves individuals with complex needs, including low-income populations, helping them manage health journeys effectively and improve outcomes. By combining clinical delivery with technology-enabled care coordination, the company aims to reduce barriers such as waiting rooms and lines and to provide dignified care that supports patients throughout ongoing management of chronic conditions and new symptoms.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies to transform the treatment of inflammatory bowel disease (IBD).

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients. The company specializes in the development of antibody-drug conjugates (ADCs) targeting novel oncology targets. By utilizing innovative technology, MBrace Therapeutics creates anti-tumor monoclonal human recombinant antibodies that specifically target cancer cells. This approach allows for the precise delivery of toxic agents directly into the cancer cells, enabling healthcare professionals to more effectively treat various forms of cancer.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Aledade is a health technology and services platform that partners with independent primary care physicians to form and operate Accountable Care Organizations in the United States. It provides data analytics, guided workflows, regulatory and contracting support, payer relationships, and local on-the-ground expertise to help practices transform operations, optimize care delivery, and align incentives around value-based care. The platform integrates care data across the continuum, offers practice management tools, and supports governance and policy guidance to enable autonomous physician groups—from small practices to multispecialty networks and community health centers—to improve patient outcomes while reducing overall costs. Headquartered in Bethesda, Maryland, the company was founded in 2014.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Celcuity is a clinical-stage biotechnology company that discovers new cancer sub-types and therapeutic options using its proprietary CELsignia diagnostic platform. This platform analyzes living tumor cells to identify specific abnormal cellular processes driving cancer, enabling the development of targeted therapies for patients.

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Mythic Therapeutics is a biotechnology company specializing in innovative cancer therapeutics. It focuses on enhancing antibody-drug conjugates (ADCs) and other antibody-based therapies using advanced protein engineering techniques, aiming to boost potency without compromising safety.

Suki develops AI-driven voice solutions for healthcare providers. Its primary product, Suki Assistant, uses artificial intelligence and natural language processing to create detailed clinical notes during or after consultations, enabling physicians to complete administrative tasks more efficiently.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing Targeted Radiotherapy (TRT) treatments aimed at benefiting cancer patients. The company focuses on innovative TRT products, utilizing the extensive business experience and networks of its founders in cross-border product development and deal-making. By targeting the Chinese market, Ablaze Pharmaceuticals seeks to provide effective cancer treatment options tailored to the needs of patients in the region.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Nuvalent is a biotechnology company focused on developing targeted therapies for clinically proven kinase targets in cancer. Leveraging expertise in structure-based design, Nuvalent creates innovative small molecules with exquisite target selectivity to overcome resistance and minimize adverse events.

GH Research is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders, with an emphasis on treatment-resistant depression. It is advancing novel and proprietary mebufotenin (5-MeO-DMT) therapies, including inhalable and intravenous product candidates, to provide transformative treatment options for patients who do not respond to existing therapies. The portfolio includes GH001, an inhalable mebufotenin candidate, and GH002, an intravenous candidate. The company concentrates its activities in research and development to create practice-changing solutions for depression.

Graphite Bio is a clinical-stage gene editing company focused on targeted DNA integration to treat serious diseases. Its platform aims to precisely insert, repair, or replace genetic sequences by integrating therapeutic cargoes at predefined genomic locations, enabling correction of mutations or replacement of disease-causing genes while preserving normal regulatory control. Based in South San Francisco, the company pursues high-efficiency precision gene editing to address underlying causes of disease.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Artiva Biotherapeutics, Inc. is a San Diego-based biotechnology company focused on developing and manufacturing cellular immunotherapies for cancer treatment. Founded in 2019, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating both hematologic cancers and solid tumors. The company's product pipeline includes therapies that target CD20 and CD19 in B-cell lymphomas, as well as HER2 in various solid tumors. Artiva is committed to harnessing the therapeutic potential of NK cells while addressing challenges in their scalability and manufacturing. Its mission centers on delivering effective and safe cell therapies that are readily accessible to cancer patients in need.

Sitka is a healthcare technology company that develops a telehealth and video platform to connect patients with clinicians across specialties. The platform enables primary care providers to access a virtual specialty network and supports collaboration among endocrinology, neurology, orthopedics, pulmonology, rheumatology, and related fields. It also offers personalized, one-on-one consultation on imaging results, such as MRI, with board-certified musculoskeletal doctors to inform care decisions. The company aims to streamline the care cycle, upskill primary care, and improve patient outcomes through accessible, expert guidance. Sitka originated in San Francisco in 2018.

MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients. The company specializes in the development of antibody-drug conjugates (ADCs) targeting novel oncology targets. By utilizing innovative technology, MBrace Therapeutics creates anti-tumor monoclonal human recombinant antibodies that specifically target cancer cells. This approach allows for the precise delivery of toxic agents directly into the cancer cells, enabling healthcare professionals to more effectively treat various forms of cancer.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

LianBio is a biopharmaceutical company founded in 2019, headquartered in Shanghai, China, with an additional office in Princeton, New Jersey. The company is dedicated to the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as addressing other unmet medical needs in Greater China and major Asian markets. LianBio focuses on in-licensing assets and collaborates with leading partners to enhance its pipeline, which includes clinically validated product candidates across various therapeutic areas such as cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory indications. The company aims to accelerate the availability of innovative medicines to improve patient outcomes through a science-driven approach.

Federation Bio Inc., established in 2018 and headquartered in South San Francisco, California, specializes in the development of microbial therapeutics targeting diseases where the human microbiome holds curative potential. The company's platforms focus on secondary hyperoxaluria and explore treatments for metabolic disorders, immune diseases, and cancer. Federation Bio's approach involves leveraging naturally occurring or engineered bacteria alongside a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Mythic Therapeutics is a biotechnology company specializing in innovative cancer therapeutics. It focuses on enhancing antibody-drug conjugates (ADCs) and other antibody-based therapies using advanced protein engineering techniques, aiming to boost potency without compromising safety.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

Founded in 2019 and headquartered in Palo Alto, California, Iris Medicine specializes in developing RNA therapeutics for treating genetic diseases. Its proprietary platform targets repeat sequences in RNA transcripts to selectively modulate them, focusing on neurological disorders.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Suki develops AI-driven voice solutions for healthcare providers. Its primary product, Suki Assistant, uses artificial intelligence and natural language processing to create detailed clinical notes during or after consultations, enabling physicians to complete administrative tasks more efficiently.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Concentric Analgesics is a biotechnology company developing non-opioid therapeutics for managing acute and chronic pain, with a focus on single local administration to target pain at the source while limiting systemic exposure. Its products aim to provide effective relief without numbness or weakness during procedures and to simplify ongoing care for patients with osteoarthritis and other conditions. The company is advancing treatments for post-surgical pain, chronic osteoarthritis pain, and refractory pain, including CA-008, an injectable capsaicin prodrug for acute post-surgical pain; CA-051 for epidural administration to treat refractory pain from cancer or amputation; and an injectable therapy for chronic pain associated with osteoarthritis. Founded in 2014, it is based in San Francisco, California.

Attune Pharmaceuticals, Inc. is a biotechnology research and development company based in New York, established in 2015. The company specializes in the discovery and development of novel orally-administered small molecule therapeutics aimed at treating rare diseases. Attune Pharmaceuticals focuses on creating innovative drug compounds, including heterocyclic derivatives, to address conditions such as hereditary angioedema and other rare medical ailments. Through its research efforts, the company seeks to provide effective treatment options for patients suffering from these uncommon disorders.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Suki develops AI-driven voice solutions for healthcare providers. Its primary product, Suki Assistant, uses artificial intelligence and natural language processing to create detailed clinical notes during or after consultations, enabling physicians to complete administrative tasks more efficiently.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Aledade is a health technology and services platform that partners with independent primary care physicians to form and operate Accountable Care Organizations in the United States. It provides data analytics, guided workflows, regulatory and contracting support, payer relationships, and local on-the-ground expertise to help practices transform operations, optimize care delivery, and align incentives around value-based care. The platform integrates care data across the continuum, offers practice management tools, and supports governance and policy guidance to enable autonomous physician groups—from small practices to multispecialty networks and community health centers—to improve patient outcomes while reducing overall costs. Headquartered in Bethesda, Maryland, the company was founded in 2014.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Aledade is a health technology and services platform that partners with independent primary care physicians to form and operate Accountable Care Organizations in the United States. It provides data analytics, guided workflows, regulatory and contracting support, payer relationships, and local on-the-ground expertise to help practices transform operations, optimize care delivery, and align incentives around value-based care. The platform integrates care data across the continuum, offers practice management tools, and supports governance and policy guidance to enable autonomous physician groups—from small practices to multispecialty networks and community health centers—to improve patient outcomes while reducing overall costs. Headquartered in Bethesda, Maryland, the company was founded in 2014.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines across hematology, oncology, cardiovascular, and immunology. Its portfolio includes Opdivo for cancer immunotherapy; Eliquis for stroke prevention and venous thromboembolism; Orencia for rheumatoid arthritis; Sprycel, Yervoy, Empliciti, Baraclude; Reyataz and Sustiva for HIV; and Daklinza, Sunvepra, Beclabuvir for viral infections. The company sells products through wholesalers, retail pharmacies, hospitals, government entities, and medical professionals worldwide, and pursues collaboration and licensing arrangements with Pfizer, Otsuka, Ono, Nektar, AstraZeneca, Insitro, Schrödinger, and others. It also engages in partnerships for discovery and development with multiple biotech firms and academia. Founded in 1887 and headquartered in New York, the firm has a strong presence in immuno-oncology and focuses on innovative therapies and global reach.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

PowerVision, Inc. is a medical device company based in Belmont, California, focused on developing advanced intraocular lenses (IOLs) designed to restore vision for individuals affected by presbyopia and cataracts. Established in 2002, the company has created the FluidVision accommodating intraocular lens technology, which simulates the natural function of a healthy eye. This innovative lens utilizes a small amount of fluid to adjust its shape dynamically, allowing for clear vision at various distances. PowerVision aims to address the vision challenges faced by millions, particularly the over 20 million individuals in the U.S. with cataracts and the more than 90 million affected by presbyopia. The FluidVision lens represents a significant advancement in vision correction, potentially freeing patients from the need for glasses or other vision correction methods. In 2019, PowerVision was acquired by Alcon Laboratories, Inc.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Spirox, Inc. is a medical device company based in Menlo Park, California, that specializes in improving the quality of life for patients experiencing nasal obstruction due to nasal valve collapse (NVC). Founded in 2011 and formerly known as Nasoform LLC, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive solution for treating one of the most prevalent yet often overlooked causes of nasal obstruction. The LATERA implant is designed to address weakened lateral wall cartilage, providing ENT specialists and facial plastic surgeons with an effective option to alleviate nasal airway obstruction. As of 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan (formerly Coversin), is a dual inhibitor of complement component 5 (C5) and leukotriene B4 (LTB4), currently in clinical trials for bullous pemphigoid, thrombotic microangiopathy, and other indications.